WO2023173105A3 - Tetracycline inducer/repressor system and simplified viral particle production - Google Patents

Tetracycline inducer/repressor system and simplified viral particle production Download PDF

Info

Publication number
WO2023173105A3
WO2023173105A3 PCT/US2023/064165 US2023064165W WO2023173105A3 WO 2023173105 A3 WO2023173105 A3 WO 2023173105A3 US 2023064165 W US2023064165 W US 2023064165W WO 2023173105 A3 WO2023173105 A3 WO 2023173105A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral particle
particle production
repressor system
simplified
inducer
Prior art date
Application number
PCT/US2023/064165
Other languages
French (fr)
Other versions
WO2023173105A2 (en
Inventor
Joseph J. HIGGINS
Feng Yao
Subhrangshu GUHATHAKURTA
Original Assignee
Saliogen Therapeutics, Inc.
The Brigham And Women's Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saliogen Therapeutics, Inc., The Brigham And Women's Hospital, Inc. filed Critical Saliogen Therapeutics, Inc.
Publication of WO2023173105A2 publication Critical patent/WO2023173105A2/en
Publication of WO2023173105A3 publication Critical patent/WO2023173105A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present disclosure describes engineered inducible tetracycline promoters for AAV production.
PCT/US2023/064165 2022-03-10 2023-03-10 Tetracycline inducer/repressor system and simplified viral particle production WO2023173105A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263318598P 2022-03-10 2022-03-10
US63/318,598 2022-03-10
US202263335860P 2022-04-28 2022-04-28
US63/335,860 2022-04-28

Publications (2)

Publication Number Publication Date
WO2023173105A2 WO2023173105A2 (en) 2023-09-14
WO2023173105A3 true WO2023173105A3 (en) 2023-10-12

Family

ID=87936088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064165 WO2023173105A2 (en) 2022-03-10 2023-03-10 Tetracycline inducer/repressor system and simplified viral particle production

Country Status (1)

Country Link
WO (1) WO2023173105A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037091A2 (en) * 1997-02-20 1998-08-27 Board Of Regents, The University Of Texas System Modified retinoblastoma tumor suppressor proteins
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US20210403888A1 (en) * 2019-03-07 2021-12-30 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037091A2 (en) * 1997-02-20 1998-08-27 Board Of Regents, The University Of Texas System Modified retinoblastoma tumor suppressor proteins
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US20210403888A1 (en) * 2019-03-07 2021-12-30 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2023173105A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
EP4324999A3 (en) Set of floor panels and method for installing this set of floor panels
WO2019094725A3 (en) Genetic modification of cytokine inducible sh2-containing protein (cish) gene
MX2020007812A (en) Chemokine receptor modulators and uses thereof.
DK0455665T3 (en) Production of hybrid seeds
NO20090324L (en) Method and apparatus for operating a light source matrix
WO2022221335A8 (en) Respiratory virus combination vaccines
EP3785451A4 (en) Nonlinear control of loudspeaker systems with current source amplifier
WO2018093832A3 (en) Coated red line emitting phosphors
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
WO2023173105A3 (en) Tetracycline inducer/repressor system and simplified viral particle production
MX2017010359A (en) Fc-FUSED HIGH AFFINITY IgE RECEPTOR a-CHAIN.
MX2021008542A (en) Methods and systems for producing aav particles.
WO2020111874A3 (en) Steel plate having excellent heat affected zone toughness and method for manufacturing thereof
MX2022009476A (en) ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS.
CR20230469A (en) Anti-nectin-4-antibodies and uses thereof
WO2018131898A3 (en) Novel use of methylomonas sp. dh-1 strain
WO2020207510A3 (en) Application of gene in boosting rice grain yield
WO2019139176A8 (en) Genus nicotiana f1 hybrid and use of same
MX2022011295A (en) Gene therapy.
WO2019224548A3 (en) Methods for the production of methacrylates
EP4028167A4 (en) Operation of magnetic beads on microfluidics substrates
MX2021014484A (en) Progranulin modulators and methods of using the same.
AU2017250446A1 (en) Photocatalytic air purifier
WO2020118261A3 (en) Bacillus expression system
MX2018005950A (en) Exogenous control of mammalian gene expression through aptamer-mediated modulation of polyadenylation.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767755

Country of ref document: EP

Kind code of ref document: A2